Paper published in Nature’s Scientific Reports “Proteome-wide drug screening using mass spectrometric imaging of bead-arrays” describing drug-discovery application of Bead-AMS™ including detection of on- and off-target drug binding

AmberGen receives US Patent 9,334,530 for its Bead-AMS™ technology describing synchronization of mass spectrometric and fluorescence images of mass-tagged bead arrays

John Gillespie, former Director of R&D for 3 Johnson & Johnson businesses including their multi-billion dollar Ethicon Products business, joins AmberGen as VP of Product and Business Development

Paper published in Liver International “Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis” resulting from a collaboration between AmberGen, INOVA Diagnostics and MGH

AmberGen receives US Patent 8,906,700 providing broad coverage on PC-PURE™ technology for biomarker isolation and use in highly sensitive and quantitative assays

AmberGen and Massachusetts General Hospital (MGH) are awarded US Patent 8,852,956 for two new diagnostic autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC)

AmberGen awarded 2-year Phase II SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions

Paper published in Rapid Communications in Mass Spectrometry “Correlated matrix-assisted laser desorption/ionization mass spectrometry and fluorescent imaging of photocleavable peptide-coded random bead-arrays” describing proteomic applications of Bead-AMS™